Table 3.
Association between clinical measurements and percentage difference in serum osteoprotegerin levels
| Percentage Difference (95% CI) | P | |
|---|---|---|
| Chronic Kidney Disease-Mineral and Bone Disorder measuresa | ||
| serum phosphate (per 1 mg/dl) | 6.5% (−1.5%, 15%) | 0.11 |
| corrected serum calcium (per 1 mg/dl) | −1.7% (−11.2%, 8.8%) | 0.74 |
| calcium X phosphorus product | 0.2% (−0.6%, 1.0%) | 0.58 |
| intact PTH ≥66 pg/ml | 3.4% (−6.1%, 13.9%) | 0.49 |
| intact PTH above KDOQI guidelines | 5.4% (−4.8%, 16.6%) | 0.31 |
| total alkaline phosphatase (per 10 U/L) | 1.5% (0%, 3.1%) | 0.05 |
| bone-specific alkaline phosphatase (per 10 U/L) | −1.5% (−4.5%, 1.5%) | 0.32 |
| cortical bone mineral content (per 50 g) | 1.6% (−2.5%, 5.9%) | 0.45 |
| Demographics and vascular risk factorsb | ||
| age (per 10 years) | 7.1% (2.6%, 11.8%) | <0.01 |
| female gender | 10.2% (0.2%, 21.3%) | 0.05 |
| black race | 1.0% (−7.7%, 10.5%) | 0.83 |
| diabetes | 8.1% (−0.8%, 17.8%) | 0.08 |
| cardiovascular disease | 9.3% (−0.1%, 19.6%) | 0.05 |
| hypertension | 5.2% (−8.2%, 20.5%) | 0.46 |
| current/former smoker | 4.3% (−4.5%, 14.0%) | 0.35 |
| systolic BP (per 10 mmHg) | 2.7% (0.6%, 4.9%) | 0.01 |
| eGFR (per 10 ml/min per 1.73 m2) | −3.9% (−6.8%, −0.8%) | 0.01 |
| serum albumin (per 1 mg/dl) | −17.0% (−25.8%, −7.2%) | <0.01 |
PTH, parathyroid hormone; KDOQI, Kidney Disease Outcomes Quality Initiative; eGFR, estimated GFR.
a
Percentage difference values were adjusted for age, gender, and race.
b
Percentage difference values were adjusted for all other demographics and vascular risk factors.